🇺🇸 FDA
Patent

US 9181231

Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia

granted A61KA61K31/385A61K31/39

Quick answer

US patent 9181231 (Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia) held by Agios Pharmaceuticals, Inc. expires Mon Nov 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Agios Pharmaceuticals, Inc.
Grant date
Tue Nov 10 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
72
CPC classes
A61K, A61K31/385, A61K31/39, A61K31/423, A61K31/428